It leads to greater inotrophy by increasing the calcium sensitivity as it binds to troponin and this results in a greater positive inotrophic force. Secondly, the drug is able to open ATP sensitive potassium channels in vascular smooth muscle cells, and the vascular dilatory effects of the drug lead to a decreased preload and afterload, putting less work on the heart. This drug is in the process of review by the FDA but has not been approved for use in the United States yet.
It enhances inotrophy by increasing calcium sensitivity as it binds to troponin, leading to a greater positive inotrophic force. Secondly, the drug can open ATP-sensitive potassium channels in vascular smooth muscle cells, and its vasodilatory effects reduce preload and afterload, easing heart work. This drug is under FDA review but has not yet been approved for use in the United States.